Triptolide down-regulates COX-2 expression and PGE2 release by suppressing the activity of NF-κB and MAP kinases in lipopolysaccharide-treated PC12 Cells

Phytotherapy Research

Volumn 26, Issue 3, 2012, Pages 337-343

  Geng, Yu ^a   Fang, Marong ^b   Wang, Jing ^b   Yu, Haiyan ^c   Hu, Zhiying ^d   Yew, David T ^e   Chen, Wei ^b,c  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d HANGZHOU RED CROSS HOSPITAL   (China)

^e and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Cyclooxgenase 2; Lipopolysaccharide; Neurodegenerative; Nuclear factor kappa B; PC12 cells; Triptolide

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROSTAGLANDIN E2; PROTEIN KINASE B; TRIPTOLIDE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; NEUROPROTECTION; NONHUMAN; PHEOCHROMOCYTOMA CELL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

4-AMINOBUTYRATE TRANSAMINASE; ANIMALS; BLOTTING, WESTERN; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DITERPENES; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPOXY COMPOUNDS; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; NEUROPROTECTIVE AGENTS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PC12 CELLS; PHENANTHRENES; PHOSPHORYLATION; RATS; RNA, MESSENGER; TRIPTERYGIUM;

RATTUS; TRIPTERYGIUM WILFORDII;

EID: 84858007126     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3538     Document Type: Article

References (33)

1. Brinker AM, Ma J, Lipsky PE, Raskin I. 2007. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68(6): 732-766. (Pubitemid 46330437)
2. Candelario-Jalil E, Fiebich BL. 2008. Cyclooxygenase inhibition in ischemic brain injury. Curr Pharm Des 14(14): 1401-1418. (Pubitemid 351982548)
3. Chen LW, Wang YQ, Wei LC, Shi M, Chan YS. 2007. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. CNS Neurol Disord Drug Targets 6(4): 273-281. (Pubitemid 47232939)
4. Chung YC, Ko HW, Bok E, et al. 2010. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 43(4): 225-232.
5. Dai YQ, Jin DZ, Zhu XZ, Lei DL. 2006. Triptolide inhibits COX-2 expression via NF-kappa B pathway in astrocytes. Neurosci Res 55(2): 154-160.
6. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39: 889-909. (Pubitemid 37130207)
7. Feng ZH, Wang TG, Li DD, et al. 2002. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329(3): 354-358. (Pubitemid 35245358)
8. Gao JP, Sun S, Li WW, Chen YP, Cai DF. 2008. Triptolide protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats: implication for immunosuppressive therapy in Parkinson's disease. Neurosci Bull 24(3): 133-142. (Pubitemid 352020326)
9. Guo JS, Cho CH, Wang JY, Koo MW. 2006. Differential effects of selective and non-selective inhibition of nitric oxide synthase on the expression and activity of cyclooxygenase-2 during gastric ulcer healing. Eur J Pharmacol 536(3): 301-308.
10. Grunblatt E, Mandel S, Maor G, Youdim MB. 2001. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem 78: 1-12. (Pubitemid 32622583)
11. Hoang T, Choi DK, Nagai M, et al. 2009. Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radical Biol Med 47(7): 1049-1056.
12. Hunot S, Brugg B, Ricard D, et al. 1997. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 94(14): 7531-7536. (Pubitemid 27345350)
13. Hurley SD, Olschowka JA, O'Banion MK. 2002. Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J Neurotrauma 19(1): 1-15. (Pubitemid 34117092)
14. Kaufmann WE, Andreasson KI, Isakson PC, Worley PF. 1997. Cyclooxygenases and the central nervous system. Prostaglandins 54(3): 601-624. (Pubitemid 27495921)
15. Jiao J, Xue B, Zhang L, et al. 2008. Triptolide inhibits amyloid-beta1-42-induced TNF-alpha and IL-1beta production in cultured rat microglia. J Neuroimmuno 205(1-2): 32-36.
16. Lee DY, Oh YJ, Jin BK. 2005. Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways. Glia 51(2): 98-110. (Pubitemid 41277344)
17. Li FQ, Lu XZ, Liang XB, et al. 2004. Triptolide, a Chinese herbal extract, protects dopaminergic neurons from inflammation-mediated damage through inhibition of microglial activation. J Neuroimmunol 148(1-2): 24-31.
18. Liu Y, Chen HL, Yang G. 2010. Extract of Tripterygium wilfordii Hook F protect dopaminergic neurons against lipopolysaccharide-induced inflammatory damage. Am J Chin Med 38(4):801-814.
19. Mattson MP, Camandola S. 2001. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 107(3): 247-254. (Pubitemid 32162153)
20. O'Banion MK. 1999. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 13(1): 45-82. (Pubitemid 29231727)
21. Panet H, Barzilai A, Daily D, Melamed E, Offen D. 2001. Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J Neurochem 77(2): 391-398. (Pubitemid 32298733)
22. Qiu D, Kao PN. 2003. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 4(1): 1-18. (Pubitemid 37062640)
23. Schwab JM, Schluesener HJ. 2003. Cyclooxygenases and central nervous system inflammation: conceptual neglect of cyclooxygenase 1. Arch Neurol 60(4): 630-632. (Pubitemid 36427982)
24. Tao X, Lipsky PE. 2000. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am 26(1): 29-50. (Pubitemid 30091720)
25. Tarabin V, Schwaninger M. 2004. The role of NF-kappaB in 6-hydroxydopamine- and TNFalpha-induced apoptosis of PC12 cells. Naunyn Schmiedebergs Arch Pharmacol 369(6): 563-569. (Pubitemid 38823988)
26. Teismann P, Tieu K, Choi DK, et al. 2003. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100(9): 5473-5478. (Pubitemid 36542729)
27. Wang Y, Mei Y, Feng D, Xu L. 2008. Triptolide modulates T-cell inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurosci Res 86(11): 2441-2449.
28. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R. 2003. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 17(3): 500-502.
29. Xu L, Chen H, Xu H, Yang X. 2008. Anti-tumour and immunomodulation effects of triptolide-loaded polymeric micelles. Eur J Pharm Biopharm 70(3): 741-748.
30. Zhang HL, Deng KQ. 1991. The stability studies of triptolide and its injection. Zhong Guo Yao Xue Zha Zhi 36: 3-4.
31. Zhao G, Vaszar LT, Qiu D, Shi L, Kao PN. 2000. Anti-inflammatory effects of triptolide in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 279: L958-L966.
32. Zhou HF, Liu XY, Niu DB, Li FQ, He QH, Wang XM. 2005. Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection. Neurobiol Dis 18(3): 441-449.
33. Zou JY, Crews FT. 2005. TNFα potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NFκB inhibition. Brain Research 1034(1-2): 11-24. (Pubitemid 40248516)